Core Viewpoint - The article discusses the performance and holdings of the Industrial and Commercial Bank of China Medical Healthcare Stock Fund, highlighting its recent net value, returns, and top holdings [1]. Fund Performance - The latest net value of the ICBC Medical Healthcare Stock Fund is 2.5580 yuan, reflecting a decrease of 1.16% - The fund's return over the past month is 3.52%, ranking 172 out of 940 in its category - Over the last six months, the return is 9.79%, with a ranking of 202 out of 914 - Year-to-date, the return stands at 12.24%, ranking 98 out of 926 [1]. Fund Holdings - The top ten holdings of the ICBC Medical Healthcare Stock Fund account for a total of 39.79%, with the following key positions: - Heng Rui Medicine: 8.90% - WuXi AppTec: 5.12% - Aier Eye Hospital: 4.94% - BeiGene: 3.77% - Zai Lab: 3.52% - New Horizon Health: 3.27% - Mindray Medical: 2.80% - Yuwell Medical: 2.76% - United Imaging Healthcare: 2.47% - Innovent Biologics: 2.24% [1]. Fund Management - The ICBC Medical Healthcare Stock Fund was established on November 18, 2014, and as of March 31, 2025, it has a total scale of 2.724 billion yuan - The fund is managed by Zhao Bei and Ding Yang, both of whom have extensive experience in the healthcare sector [1][2].

Core Viewpoint - The article discusses the approval of the KRAS G12C inhibitor, Goratirsen (brand name "Airikai"), by the National Medical Products Administration for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harboring the KRAS G12C mutation who have received at least one systemic therapy [2][3]. Group 1: Product Approval and Financial Implications - The approval of Goratirsen triggers a milestone payment of 50 million yuan to the developer, Gako Pharmaceutical, from its partner, Ailis [3]. - Lung cancer is the most prevalent and deadly malignancy globally, with non-small cell lung cancer accounting for approximately 85% of all lung cancer cases [3]. Group 2: Clinical Study Results - The approval is based on a pivotal Phase II single-arm study assessing the safety, tolerability, and efficacy of Goratirsen in patients with advanced NSCLC who have failed or are intolerant to standard treatments [3][4]. - The study included 119 NSCLC patients, with an independent review showing a confirmed objective response rate (cORR) of 49.6% (range: 40.2%-59.0%) and a disease control rate (DCR) of 86.3% (range: 78.7%-92.0%) [4]. - The median duration of response (DOR) was 14.5 months (range: 9.6-NE), median progression-free survival (PFS) was 8.2 months (range: 5.2-11.1), and median overall survival (OS) was 17.5 months (range: 13.6-NE) [4]. Group 3: Product Features and Future Developments - Goratirsen is the only KRAS G12C inhibitor approved in China that allows for once-daily oral administration, enhancing patient convenience [4]. - Ailis plans to commercialize Goratirsen and is conducting clinical studies for its use in combination with SHP2 inhibitors for first-line treatment of NSCLC, as well as for monotherapy in multiple tumor types [4].

Core Viewpoint - Shanghai Ailis Pharmaceutical Technology Co., Ltd. has announced a cash dividend distribution of RMB 0.40 per share (before tax), totaling RMB 180 million (before tax) for its shareholders, following the approval at the annual general meeting held on May 14, 2025 [1][5]. Dividend Distribution Plan - The dividend distribution is based on a total share capital of 450 million shares, with a cash dividend of RMB 0.40 per share, amounting to a total cash distribution of RMB 180 million (before tax) [1]. - The cash dividend will be distributed to all shareholders registered with China Securities Depository and Clearing Corporation Limited, Shanghai Branch, as of the close of trading on the record date [1]. Relevant Dates - The key dates for the dividend distribution are as follows: - Record date - Ex-dividend date - Cash dividend payment date [1]. Taxation on Dividends - For individual shareholders holding unrestricted circulating shares: - Those holding shares for over 1 year will not be subject to personal income tax on dividend income, receiving a net cash dividend of RMB 0.40 per share [2]. - For shares held for 1 year or less, the company will not withhold personal income tax at the time of distribution; tax will be calculated upon the transfer of shares [2]. - The actual tax burden for shareholders varies based on the holding period: - Less than or equal to 1 month: 20% tax rate, effective cash dividend of RMB 0.32 per share - More than 1 month to 1 year: 10% tax rate, effective cash dividend of RMB 0.36 per share - Over 1 year: no tax [3][4]. Distribution to Foreign Investors - Qualified Foreign Institutional Investors (QFII) will have a withholding tax of 10%, resulting in an effective cash dividend of RMB 0.36 per share [4]. - For Hong Kong market investors, the same 10% withholding tax applies, with dividends distributed in RMB [4]. Contact Information - For inquiries regarding the dividend distribution, shareholders can contact the Securities Affairs Department at 021-80423292 [4].

本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/5/30 | 2025/6/3 | 2025/6/3 | 一、 通过分配方案的股东大会届次和日期 证券代码：688578 证券简称：艾力斯 公告编号：2025-012 上海艾力斯医药科技股份有限公司 2024年年度权益分派实施公告 本次利润分配方案已经公司2025 年 5 月 14 日召开的2024年年度股东大会审议 通过。 二、 分配方案 1. 发放年度：2024年年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 分配方案： 本次利润分配以方案实施前的公司总股本450,000,000股为基数，每股派发现 金红利0.40元（含税），共计派发现金红利180,000,000元（含税）。 是否涉及差异化分红送转：否 每股分配比例 每股现 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688578 证券简称：艾力斯 公告编号：2025-013 上海艾力斯医药科技股份有限公司自愿披露 关于枸橼酸戈来雷塞片新药上市申请获得批准的公告 得益于创新的药物共晶设计和稳定的构型,戈来雷塞有良好的安全性特征， ≥3 级治疗相关不良事件发生率更低，且具有良好的消化道安全性特征。戈来雷 塞是目前国内已获批的 KRAS G12C 抑制剂中，唯一实现每日单次口服给药的 KRAS G12C 抑制剂，患者服用更加方便。 二、对公司的影响 戈来雷塞非小细胞肺癌二线治疗适应症的上市申请完成审批，标志着戈来雷 塞商业化的正式开始，有利于丰富公司的商业化管线，提升公司的销售收入。公 司已组建了专业化的营销团队，将充分利用戈来雷塞的临床治疗优势，不断完善 产品的学术推广及产品营销策略，扩大戈来雷塞获批适应症的患者群体覆盖，提 升戈来雷塞的产品销售收入，并积极推动戈来雷塞非小细胞肺癌二线治疗适应症 尽快纳入国家医保目录，惠及更多肺癌患者。 上海艾力斯医药科技股份有限公司（以下简称"公 ...

Group 1 - The company's KRAS G12C inhibitor, citric acid gorasetinib (brand name "Airikai"), has received approval from the National Medical Products Administration for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutations who have received at least one systemic therapy [1] - As of September 28, 2024, a total of 119 NSCLC patients were included in the analysis [1] - The confirmed objective response rate (cORR) assessed by the Independent Radiologic Review Committee (IRC) reached 49.6% (40.2%-59.0%) [1] - The disease control rate (DCR) was 86.3% (78.7%-92.0%) [1] - The median duration of response (DOR) was 14.5 months (9.6-NE) [1] - The median progression-free survival (PFS) was 8.2 months (5.2-11.1) [1] - The median overall survival (OS) was 17.5 months (13.6-NE) [1]

Core Viewpoint - The National Medical Products Administration has conditionally approved the innovative drug Glecirasib (brand name: Airikai) developed by Elysium, which is indicated for adult patients with advanced non-small cell lung cancer (NSCLC) harboring KRAS G12C mutations who have received at least one prior systemic therapy [1] Group 1 - The drug Glecirasib is classified as a first-class innovative drug [1] - The approval was granted through a priority review and approval process [1] - The target patient population includes adults with advanced NSCLC and specific genetic mutations [1]

Core Viewpoint - The ICBC Medical Care Stock Fund (000831) has shown positive performance with a recent net value of 2.5640 yuan, reflecting a growth of 2.07% [1] Performance Summary - The fund's one-month return is 4.48%, ranking 672 out of 1022 in its category - Over the last three months, the return is 7.69%, with a ranking of 96 out of 1009 - Year-to-date, the return stands at 12.51%, ranking 128 out of 999 [1] Holdings Overview - The top ten holdings of the fund account for a total of 39.79%, with the following key positions: - Heng Rui Medicine: 8.90% - WuXi AppTec: 5.12% - Aier Eye Hospital: 4.94% - BeiGene: 3.77% - Zai Lab: 3.52% - New Horizon Health: 3.27% - Mindray Medical: 2.80% - Yuyue Medical: 2.76% - United Imaging Healthcare: 2.47% - Innovent Biologics: 2.24% [1] Fund Details - The ICBC Medical Care Stock Fund was established on November 18, 2014, and as of March 31, 2025, it has a total scale of 2.724 billion yuan - The fund is managed by Zhao Bei and Ding Yang [1][2]

Summary of the Conference Call for Ailis Company Overview - Ailis is focused on the oncology sector, particularly lung cancer treatments, with its core product being Furmetinib, a third-generation EGFR TKI [2][3][4][7]. Key Points and Arguments Product Performance and Market Potential - Furmetinib's sales are projected to exceed 3.5 billion yuan in 2024, with a peak domestic sales estimate of 8 billion yuan [2][3]. - The product has achieved significant commercial success since its launch, with cumulative sales surpassing 6.5 billion yuan since 2021 [2][8]. - Ailis is expanding its indications for Furmetinib, currently involved in six registered clinical studies [3][4]. - The company has partnered with ArriVent to develop a first-line therapy for EGFR 20 exon insertion mutation lung cancer, with top-line data expected by the end of 2025 and a market entry anticipated in 2027 [2][3][9]. Financial Projections and Valuation - Ailis's estimated average PE ratio for 2025 is 21.16, compared to 28 times for comparable companies like Betta Pharmaceuticals and Terbium Biotech [2][6][17]. - The total pipeline valuation is projected at 47.03 billion yuan, indicating a potential growth of 20%-30% [2][6][17]. - The company expects a net profit of 1.85 to 1.9 billion yuan for 2024, with a sales expense ratio reduced to around 40% [2][5][8]. Collaborations and New Drug Introductions - Ailis has introduced KRAS G12C and RET inhibitors, with expectations for approval and inclusion in medical insurance by 2025, which will synergize with Furmetinib [2][4][9]. - The introduction of new drugs is expected to significantly contribute to revenue growth, with projections for the sales of these new drugs reaching approximately 700 million yuan [2][15]. Market Dynamics and Competitive Landscape - The third-generation EGFR TKI market is projected to reach 28 billion yuan in 2023, with Ailis's products positioned to capture a significant share [12][13]. - The company is also exploring the development of fourth-generation EGFR TKIs, although the R&D challenges are acknowledged [10]. Future Opportunities - Ailis is targeting various opportunities in non-small cell lung cancer treatment, including addressing rare mutations and overcoming resistance to third-generation EGFR TKIs [11]. - The company is expanding its marketing team to enhance its reach, covering 31 provinces and 4,800 hospitals [8]. Additional Important Insights - The competitive landscape for KRAS G12C inhibitors is noted to be challenging, with Ailis's product expected to capture a market share of around 1.8 billion yuan [16]. - The collaboration with ArriVent is highlighted as a strategic move to enhance Ailis's market presence internationally [9][17]. This summary encapsulates the critical insights from the conference call, focusing on Ailis's strategic positioning, product performance, financial outlook, and market opportunities.

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative price increase of over 20% compared to the market benchmark within the next six months [5][22]. Core Insights - The company has demonstrated impressive performance with a revenue of 3.56 billion yuan in 2024, reflecting a year-on-year growth of 76.3%, and a net profit of 1.43 billion yuan, up 122% year-on-year [2][5]. - The sales expense ratio has improved, decreasing by 5.9 percentage points to 39.7% in 2024, while the net profit margin increased by 8.27 percentage points to 40.2% [2][3]. - The innovative pipeline is progressing steadily, with multiple clinical trials for the drug Vomeletin ongoing, targeting various indications [4][5]. Financial Performance - In Q4 2024, the company achieved a revenue of 1.02 billion yuan, a 52.8% increase year-on-year, and a net profit of 370 million yuan, up 57% year-on-year [2]. - For Q1 2025, the company reported a revenue of 1.1 billion yuan, a 47.9% increase year-on-year, and a net profit of 410 million yuan, reflecting a 34.1% growth [3]. - The projected net profits for 2025, 2026, and 2027 are estimated at 1.7 billion yuan, 2.03 billion yuan, and 2.49 billion yuan, respectively, indicating a strong growth trajectory [5]. Cost Management - The company has effectively optimized its cost structure, with a decrease in the management expense ratio to 4.6% in 2024, down 1.9 percentage points year-on-year [2]. - The research and development expense ratio also saw a decline to 8.8%, down 6.7 percentage points year-on-year, indicating efficient allocation of resources [2]. Market Position and Growth Potential - The company is in a rapid growth phase with Vomeletin's market expansion and the introduction of new products, highlighting its long-term growth potential [5]. - The introduction of the KRASG12C inhibitor, Goretinib, is expected to enhance the company's product offerings and market presence [4][5].